CPLX2

Across TCGA pan-cancer cohorts, CPLX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPLX2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPLX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CPLX2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where CPLX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.506	0.218	<.001	98	view →
LUAD	DFS	Median	All	0.819	0.969	.022	9	view →
GBM	DFS	Quartile	All	0.819	0.559	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CPLX2–PDAC (OS)

Open the PDAC breakdown →